Thermo Fisher Scientific expands its cell therapy development and manufacturing capabilities with new facility in San Francisco, CA.
It’s not uncommon for companies who launch commercial drug products in the pre-filled syringe format to do so after initially using other product formats such as vials for the development and clinical trial phases. Switch-overs need careful and strategic consideration because doing so requires investment in the new format but also offers critical patient benefits and improved stakeholder outcomes.
Download this whitepaper to learn:
Author(s): Vincenza Pironti, PhD., Global SME, Sterile Drug Product
Madhu Raghunathan, Director, Product Management
Roman Hlodan, Staff Scientist, R&D